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Human exposure to ionizing radiation (IR) disrupts normal metabolic processes in cells 
and organs by inducing complex biological responses that interfere with gene and protein 
expression. Conventional dosimetry, monitoring of prodromal symptoms, and peripheral 
lymphocyte counts are of limited value as organ- and tissue-specific biomarkers for 
personnel exposed to radiation, particularly, weeks or months after exposure. Analysis of 
metabolites generated in known stress-responsive pathways by molecular profiling helps 
to predict the physiological status of an individual in response to environmental or genetic 
perturbations. Thus, a multi-metabolite profile obtained from a high-resolution mass 
spectrometry-based metabolomics platform offers potential for identification of robust 
biomarkers to predict radiation toxicity of organs and tissues resulting from exposures to 
therapeutic or non-therapeutic IR. Here, we review the status of radiation metabolomics 
and explore applications as a standalone technology, as well as its integration in systems 
biology, to facilitate a better understanding of the molecular basis of radiation response. 
Finally, we draw attention to the identification of specific pathways that can be targeted 
for the development of therapeutics to alleviate or mitigate harmful effects of radiation 
exposure.
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iNTRODUCTiON
Exposure to ionizing radiation (IR) can cause deleterious effects in humans, dependent on dose 
and rate of exposure (Figure 1). Sub-lethal doses may cause few or no acute symptoms; however, 
longer term follow-up may reveal radiation-induced carcinogenesis, severely affecting quality of 
life of exposed personnel. Therefore, there is a need to develop biomarkers indicative of early and 
delayed whole body and organ-/tissue-specific injury that may facilitate the clinical management of 
afflicted populations.
Understanding therapeutic response to radiation is of critical clinical importance since approxi-
mately two-thirds of cancer patients receive radiotherapy (1). The Cancer Biology/Radiation Biology 
Task Force appointed by the American Society for Radiation Oncology (ASTRO) Board of Directors 
recently recommended the study of tumor metabolism, as well as tumor genomics and epigenet-
ics, as promising areas for research for the advancement of radiotherapy treatment of cancer (2). 
Furthermore, the general population is subjected to low-levels of radiation due to environmental or 
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occupational exposure on a routine basis (3). Inadvertent catas-
trophes such as the Fukushima disaster and the increasing risk of 
terrorism necessitate a diagnostic and monitoring platform that is 
easily deployable, reproducible, accurate, and rapid for evaluation 
of radiation exposure. Since metabolomics is a high-throughput 
technology, it is well suited for this goal and can be performed 
on readily accessible biological samples, such as urine or serum.
In the event of mass casualty incidents, biomarkers can offer a 
tool to triage used to segregate “at risk” population (4). Although 
nausea, vomiting, and erythema may manifest as acute radiation 
syndromes of 1–4 Gy, there is a latent period before the physi-
ological signs develop (5). Employing metabolomics to analyze 
and quantify variations in concentrations of small molecule 
metabolites comprising the metabolome can help to identify 
the physiological status of an individual even before symptoms 
become apparent (6).
High thorough-put technologies and analyses have fueled 
novel scientific discoveries, but thus far, biological “big data” has 
failed to be translated to a real-world understanding of pathology 
phenotype profiling (7). The transition from “omic” bench-work 
to patient-bedside is complicated by biological processes that are 
subjected to regulatory mechanisms. Epigenetics, microRNA 
interference, and post-translational modifications of proteins are 
reflected in genomics, transcriptomics, and proteomics analysis 
and provide an indirect image of cellular phenotype while 
metabolomics can be used as a “read-out” of current physiol-
ogy (7, 8). Since metabolites are not subject to many complex 
post-processing mechanisms, they are deemed to be closest to 
cellular phenotype and hence valuable for developing a robust 
band of biomarkers (8). Metabolomics has augmented discovery 
of biological biomarkers for pathway perturbations in cancer 
(8–11), neurological disorders (12, 13), cardiovascular disease 
(3, 4, 14–16), diabetes (5, 17, 18), and alcohol-induced liver injury 
(19). Finally, metabolomics has helped to elucidate the biology of 
treatment responses and environmental exposures (20–22).
Metabolomics is an emerging new discipline that identifies 
and quantifies small molecules (50–150 Da) that are downstream 
of genomic, transcriptomic, and proteomic processes. Use of 
this technology is fast gaining credence for the development 
of molecular signatures of various pathological condition and 
therapies. Metabolomics-based molecular profiling has been used 
successfully for assessing qualitative and quantitative response of 
exposure to IR. The field has also seen rapid and ongoing develop-
ment of statistical tools for analyzing data from metabolomics 
profiling that is critical for drawing meaningful interpretation for 
clinical and translational applications.
Herein, we review current status of metabolomics technolo-
gies, data analytics, database utilization, and pathway analyses 
that are driving the advancement of this approach for developing 
biomarkers predictive of exposure to IR and concomitant risk of 
developing specific pathologies over time. We discuss the impor-
tance of metabolomics studies using cellular or tissue, rodent, and 
primate models in the context of radiobiology as well as the future 
of clinical and translational radiation research through a systems-
wide integration and statistical modeling of metabolomics with 
recommendations for standardization of sample collection and 
data analysis processes for future studies.
MeTABOLOMiCS TeCHNOLOGieS, DATA 
ANALYSiS, AND SCOPe OF 
APPLiCATiONS
The promise of metabolomics as a scientific tool has been fueled 
largely by the advancement in nuclear magnetic resonance (NMR) 
and mass spectrometry (MS). NMR is an analytical tool that uti-
lizes the resonance absorption profiles of molecules in a magnetic 
field. MS generates profiles of mass to charge ratios from ionized 
molecules that are separated by a mass analyzer and detected 
by an ion detector (9, 10). The choice of technological platform 
for a particular experiment depends on the type of the available 
biological sample and its characteristics, the research question of 
interest, sensitivity and associated costs. Historically, NMR has 
been the platform of choice, because it is a standalone technology, 
samples required no processing (non-destructive technique), and 
it provides unambiguous structural information about metabo-
lites (11). Additionally, NMR spectroscopy with magic angle 
spinning allows for the analysis of intact tissues (12). Although 
several techniques such as J-resolved, TOCSY, and HSQC spectra 
exist to enhance NMR sensitivity (13, 14), the dynamic range 
is not ideal for detection and identification of low abundance 
biomarkers. Over the last decade, MS has become increasingly 
popular due to its superior sensitivity compared to NMR mainly 
because of rapid advancements in resolution and sensitivity of 
the instruments that facilitate the detection of low abundance 
compounds. For instance, a typical analytical run using a C18 
reverse chromatography in conjunction with time of flight MS 
yields around 5000–8000 features. Targeted MS approaches with 
optimization can achieve femtomolar sensitivities depending 
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on the compound of interest. Although methodologies of direct 
infusion (DI) MS (without chromatographic separation) exist, 
more sensitive and high-throughput MS analysis is achieved by 
employing a chromatographic platforms including gas chroma-
tography (GC), liquid chromatography (LC), capillary electro-
phoresis (CE), or supercritical fluid chromatography (SFC) in 
conjunction with high-resolution MS (9). Frequently, the use of a 
specific chromatographic method for resolving small molecules 
in complex biological mixture is based on the characteristics of 
the metabolites of interest. Typically, following chromatographic 
separation, small molecules are ionized using electrospray ioniza-
tion and are resolved within the mass analyzer based on mass 
to charge ratio and get detected in real time. Development of a 
variety of ionization techniques (e.g., electron ionization, chemi-
cal ionization, fast atom bombardment ionization, electrospray 
ionization, and matrix-assisted ionization), mass analyzers (e.g., 
quadrupole, magnetic sector field, electric sector field, time of 
flight, and ion trap), and ion detectors (electron multiplier, 
multichannel plate, and Faraday cup) facilitate the analysis of 
small molecules metabolites that are known to be structurally 
and chemically diverse (15).
The analyses of NMR and MS metabolomics data share 
many common pre-processing and post-processing steps. Pre-
processing describes conversion of raw spectral data into qualita-
tive and quantitative information and involves such steps as outlier 
screening, baseline correction, transformation, normalization, 
and peak binning. The end-product of NMR pre-processing is a 
matrix of chemical shifts and intensities for samples, contrary to 
the end-product of MS pre-processing which is a matrix of mass to 
charge ratios, retention times, and abundance values for samples. 
However both NMR and MS post-processing of metabolomics 
data involve cleaning and analyzing the data, and translating 
the data to biologically relevant interpretations. Post-processing 
steps involve statistical analysis such as principal component 
analysis (PCA), support vector machines, and database query to 
make putative identifications (16–19).
eFFeCT OF RADiATiON ON 
BiOMOLeCULeS
Radiation biology involves the study of effects of energy deposi-
tion by IR on biological systems and the subsequent cellular 
response and damage as a consequence of both direct and indirect 
effects of the radiation. Direct damage due to radiation is caused 
by breakage of specific bonds within 10−14  s of exposure in the 
biomolecules (S–H, O–H, N–H, and C–H). Indirect damage is 
related to water radiolysis and the rapid formation of reactive 
oxygen species (ROS), which occurs within 10−12  s of IR expo-
sure. Subsequent formation of secondary ROS such as superoxide 
(O2
−), hydrogen peroxide (H2O2), and reactive nitrogen species 
(RNS) such as peroxynitrite anion (ONOO−) and peroxynitrous 
acid (ONOOH) also cause further damage to DNA and the cel-
lular compartments, misbalance the stoichiometry of biochemical 
reactions, and perturb functionally relevant pathways, all within 
1 ms of exposure (20–22). Furthermore, IR exposure induces the 
formation of endogenous ROS and RNS through mitochondrial 
electron transport chain, stress mechanisms, and elevates the 
expression of ROS producing enzymes. For instance, IR influences 
the overexpression of inducible nitric oxide synthase (iNOS), 
which leads to an increased level of NO, a precursor of ONOO−. 
Similarly, IR induces the expression of NADPH oxidase, which 
converts oxygen and NADPH to superoxide (O2
−) and hydrogen 
ion (23, 24). Increased NADPH oxidase levels can be observed 
months after irradiation. Together with renin–angiotensin system 
member peptide and its receptor (AT1R), NADPH oxidase pro-
duces ROS (25, 26). The generation of oxidants and reductants as 
a consequence of IR exposure subsequently results in biomolecule 
damage as illustrated in Figure 2 (27).
DNA is particularly vulnerable to ROS-induced damage, 
resulting in single-base damage, sugar damage, single- and 
double-strand breaks, DNA–DNA, and DNA–protein cross links. 
As a result, metabolites related to DNA damage and repairs have 
been frequently reported in biodosimetry studies using targeted 
and untargeted metabolomics approaches.
The ability of cells to survive after DNA damage lies in mobiliz-
ing oxidative stress-defense mechanisms. Initially, low-molecular 
weight endogenous antioxidants (e.g., thiols, glutathione, ascor-
bate, melatonin, lipoic acid Coenzyme Q10, Vitamin E, etc.) 
neutralize water radiolysis products, oxidized molecules, and 
peroxynitrite. Subsequently, levels of endogenous antioxidants 
fall rapidly, and enzymatic detoxification combats secondary 
elevated endogenous ROS as a secondary level of cellular protec-
tion. For instance, superoxide dismutases (SODs) convert O2
−  to 
H2O2 and O2. H2O2 is then detoxified by oxyredoxins and glu-
tathione peroxidases. Persistent oxidative stress causes activation 
of transcription factors, which bind to sequences that encode for 
detoxifying enzymes (e.g., SOD, GPx, glutathione S-transferase, 
heme oxygenase-1 among others) (28–32). These processes 
impact endogenous metabolites, for instance, increased oxidative 
stress leads to mitochondrial impairment causing a disruption 
in electron transport chain and oxidative phosphorylation. 
Additionally, lipid transport across the mitochondrial membrane 
is affected. Secondary causes of IR exposure result in membrane 
damage due to lipid oxidation and peroxidation events (33).
Nevertheless, depending on the level of damage, detoxifica-
tion and protective processes of the cells are often compromised, 
leading to DNA damage. Activation of cell cycle checkpoints and 
DNA repair mechanisms follow multiple kinase cascades, DNA 
repair signaling, cell cycle arrest, and apoptosis. DNA damage 
response mechanisms are activated by sensor, transducer and 
effector proteins. The DNA damage sensor complex MRN 
(MRE11, Rad50, and NBS1) helps recruit ATM and ATR to the 
DNA damage sites. Downstream of their signal transduction 
are histone H2AX, checkpoint kinases Chk1 and Chk2, and 
adenosine monophosphate-activated kinase (AMPK). These 
signals activate important DNA damage response proteins and 
transcription factors such as p53, BRCA1, Nbs1, C-Abl, mTOR, 
p21Cip1, and p27kip1 (34, 35). Mediation of many of these 
components can result in cell cycle arrest at G1/S and G2/M and 
subsequent apoptosis. ATM, also known as the ataxia telangiec-
tasia mutated gene, mediates phosphorylation of H2AX when 
there are double strand breaks in DNA, whereas the ATR gene 
mediates H2AX phosphorylation due to single strand breaks in 
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S-phase arrested cells (36). Until recently, it was believed that 
H2AX activation is mostly mediated by ATM, but recent studies 
suggest that ATR is responsible for the majority of both early 
and late (after 24-h) responses to ROS even in non S-phase cells 
(36). However, mechanisms of this activation are still unclear. 
Interestingly, H2AX histone alterations have been found after 
low-dose and high-dose radiation exposure (34–37).
In addition to DNA, polyunsaturated fatty acids (PUFA) and 
other lipids that are integral components of cell membrane are 
highly susceptible to IR exposure damage (38, 39). Cellular dam-
age involving lipids after IR also includes sphingolipids, espe-
cially ceramide (40). Ceramide is produced by sphingomyelinase 
enzyme, which relocates from lysosomes into the cytoplasm after 
IR. Excessive production of ceramide may lead to apoptosis as 
well as enlargement of lipid raft micro domains into lipid plat-
forms; these enlargements are enriched in receptors, proteins, and 
nuclear factors, which changes intracellular signaling. Overall, 
IR-induced lipid alterations may cause increased membrane 
permeability, changes in ion gradients, additional radical genera-
tion, changes in signaling, and ultimately cell death. IR-induced 
protein damage is principally mediated by ROS, which can be 
monitored using MS techniques. For instance, hydroxyl ion initi-
ates generalized breakage of protein backbone, although amino 
acids with aromatic rings are particularly vulnerable. On the 
other hand, IR-induced protein carbonylation is mostly specific 
to amino acids such as lysine, cysteine, histidine, threonine, pro-
line, glutamate, asparagine, and arginine (41, 42). Perturbation 
of proteins by radiation exposure may cause signal transduction 
alterations, RNS formation, and damage of other biomolecules. 
Recently, techniques to improve radiation therapy, such as proton 
beam therapy have emerged, both to reduce normal tissue toxicity 
and to facilitate a more targeted approach. Proton beam therapy 
has been shown effective in treating small brain tumors, head 
and neck tumors, chordomas, due to an improved conformal 
delivery, permitting dose escalation. By virtue of lower off-target 
radiation exposures, proton beam therapy may be superior to 
conventional radiation for benign lesions, by reducing the risk 
of secondary malignancies (43). However, there is little research 
being done to understand how protons affect biological processes 
at molecular level.
MeTABOLOMiCS STUDieS iN CeLLULAR 
OR TiSSUe MODeLS
In an effort to complement transcriptomic and proteomic stud-
ies on radiation exposure, Patterson and colleagues conducted 
a study of radiation markers in  vitro using a metabolomics 
approach. The differential generation of hydrophilic metabo-
lomes in TK6 and BJ cell lines were studied over a pre-determined 
interval after radiation exposure using ultra-performance liquid 
chromatography with electrospray ionization time-of-flight mass 
spectrometry (UPLC-ESI-TOFMS). Interestingly, this group 
used an innovative visualization tool that had been developed 
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for analysis of gene expression data by clustering closely related 
metabolomes. Predictably, the depleted metabolomes were found 
to be related to oxidative stress response and DNA damage. AMP 
levels were found to be significantly depleted 1 h post-radiation 
representing an acute effect. On the other hand, metabolites like 
glutathione, NAD+, and spermine showed significant differences 
at 1 h followed by normal levels at 8 h; however, by 16 h following 
radiation exposure, the endogenous levels of these metabolites 
were the same as that observed at 1  h post-radiation (44). In 
addition, response to radiation differed in the two cell lines 
emphasizing differential radio sensitivity.
In order to understand ATM-mediated DNA repair mecha-
nisms, we have reported a study where isogenic cell lines were 
irradiated, and the cellular response was studied overtime. We 
used a hypersensitive cellular strain of ataxia telangiectasia 
fibroblasts, AT5BIVA, as well as second genetically engineered 
cell line (ATCL8), with the exogenously introduced wild-type 
ATM gene. Metabolomic profiling of irradiated AT5BIVA 
revealed dysregulated glycerophospholipid metabolism and 
phospholipid degradation. In contrast, metabolomic profiling of 
the ATM proficient line (ATCL8) revealed changes in abundance 
of biomolecules participating in many pathways including purine 
metabolism, linoleic acid metabolism, pentose and glucuronate 
interconversions, and fructose and mannose metabolism after 
irradiation. This study helped correlate alterations in radiation-
induced metabolic responses based on a single-gene perturbation. 
Furthermore, a preponderance of proteomic evidence strength-
ened the conclusions drawn from metabolomics profiling (45).
With the help of CE mass spectrometry (CE-MS), Lee and 
Britz-McKibben identified metabolomes associated with radia-
tion-induced apoptosis in human leukocytes (46). Flow cytometry 
allowed differentiation between apoptotic, non-apoptotic, and 
necrotic cells. Furthermore, staining in flow cytometry was used 
to differentiate early and late apoptotic cell lines. The correlation of 
flow cytometry with CE-MS data revealed up-regulation of argi-
nine, glutamine, creatine, and proline levels, in comparison with 
reduced glutathione levels in irradiated versus sham-irradiated 
leukocytes. As discussed in the Patterson study, the metabolites 
identified in this study belong to pathways of oxidative stress and 
energy metabolism. Despite the diversity of methods used by 
the two studies, these cellular processes identified were indeed 
comparable. Nevertheless, further research is necessary to resolve 
the generality of these findings and their attribution to cellular 
response to radiation or to determine if these metabolites are 
non-specific markers of cellular response to stress.
Another study analyzed the effects of IR on surviving immune 
T cells from previously irradiated animals and the observed 
changes in the cellular metabolic profiles. Li and colleagues con-
cluded that IR impaired the metabolic reprograming of activated 
T cells This led to a decrease in effectiveness of vital metabolic 
mechanisms needed for activation including, “glucose uptake, 
glycolysis, and the energy metabolism.” This approach could be 
used to investigate how transformations of T cells can be used 
as potential targets for combined modality therapeutic methods 
such as radiotherapy and immune therapy (47).
In another study, human keratinocytes when irradiated to a 
low dose (<10 cGy) exhibited time- and dose-related disruptions 
in DNA/RNA damage repair and lipid and energy metabolomic 
pathways. The difference in the levels of the metabolites showed a 
delayed response to the low-dose IR as the shift in the metabolite 
levels are different from controls at 48 h and not at previous time 
points. This response imitates the radiobiology of tissues irradi-
ated to high doses, suggesting that biomarkers may be present 
even at low-dose radiation exposures (48).
MeTABOLOMiCS STUDieS iN RODeNT 
MODeLS
Murine and rat models have been extensively used for radia-
tion metabolomics studies since they can be performed under 
controlled conditions (age, gender, genotype, and diet) so as to 
derive radiation specific inter-subject metabolite comparison. 
Also, specimens from rodents (e.g., serum, urine, intestine or 
lung) are readily available. Some of the earliest metabolomics 
studies of radiation exposure in rodent models used urine as an 
analyte. Tyburski and colleagues used a targeted metabolomics 
approach to investigate β-thymidine and N-hexanoylglycine 
urinary biomarkers after radiation exposure (49). In this study 
of metabolomic characterization of radiation response, animal 
handling was found to be extremely important for the accuracy 
of the results; early in the study, one component of the mouse 
chow was erroneously identified as a marker of radiation sensitiv-
ity. Nevertheless, subsequent experiments under more controlled 
dietary and caging protocols revealed more conclusive results (50). 
Dose-related increase in urinary thymidine, 2′-deoxyuridine, 
2′-deoxyxanthosine, xanthine, and xanthosine were observed 
in the mice-irradiated with sub-lethal dose of gamma rays. The 
metabolites identified by Tyburski and colleagues differed from 
more classical markers of radiation exposure related to oxidative 
damage to DNA structure (e.g., 8-hydroxy-2′-deoxy guanosine 
thymine glycol and thymidine glycol), suggesting that gamma 
radiation may damage DNA differently than other forms of 
radiation.
Untargeted metabolomics profiling and subsequent PCA 
analysis of rat serum 24-h post-irradiation with 0, 0.75, 3, and 
8 Gy doses revealed nine serum markers of radiation exposure. 
Inositol, serine, lysine, glycine, threonine, and glycerol were 
upregulated, whereas isocitrate, gluconic acid, and stearic acid 
were down-regulated (51).
Another study used UPLC-ESI-TOFMS coupled with PCA 
for the analysis of serum from mice exposed to 3 Gy of radia-
tion (a non-lethal dose) at 2, 4, 6, and 8 months of age; which 
demonstrated elevation of DNA damage biomarkers (e.g., thy-
midine, xanthosine, 2′-deoxyuridine) and N1-acetylspermidine. 
The levels of some metabolites such as 2′-deoxyuridine and 
xanthine did not get affected when exposed at long intervals to 
continuous irradiation. Findings from this study emphasize the 
role of polyamine metabolism toward impacting the efficiency 
of DNA damage and repair that shows a progressive decline 
with age. Prediction of exposed mice based on xanthosine and 
2′-deoxyuridine urine metabolomic profile was robust (82 and 
98%, respectively) irrespective of age and exposure history, 
which suggests a non-invasive signature for sub-lethal radiation 
exposure (52).
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The use of metabolomic technology is likely to yield a panel 
of biomarkers, and not just a single molecule, that can be poten-
tially used to identify the biological effects of radiation (53). 
Nevertheless, some metabolites may be identified by targeted 
metabolomics approaches as individual biomarkers. In a murine 
model study by Jones and colleagues, such an approach was 
utilized (54). Citrulline and retinoic acid were investigated as 
biomarkers for dose-related analysis of radiation damage to the 
intestine and lung, respectively. Three strains of mice exposed to 
15 Gy of radiation to the lung showed abnormal lung histology and 
accompanying decrease in retinoic acid levels 24 h and 180 days 
post-irradiation with metabolomic quantification of lung tissue 
by LC-MS/MS. The group of mice exposed to full-body irradia-
tion doses of 8, 9, and 10 Gy had a 50–60% decrease in plasma 
citrulline concentration 4  days post-irradiation compared to 
controls, whereas mice exposed to 11–15 Gy doses demonstrated 
a 90% decrease in plasma citrulline. At day 6, mice exposed to 
lower doses of radiation recovered circulating citrulline levels, 
whereas mice with 11–12  Gy levels of exposure had <50% of 
that of the control levels, and mice exposed to 13–15 Gy had no 
recovery in circulating citrulline levels. Intestinal histology did 
correlate with citrulline levels as well.
In another murine model study, radiation damage to intestinal 
tissues was investigated (55). Metabolomic profiles of mice at 1 
and 4 days post sub-lethal irradiations at 4 and 8 Gy to identify 
markers of GI injury. Utilizing MS and multivariate analysis, 
lipids, glutamate, tryptophan, taurocholate, and the dipeptide 
Cys–Gly were identified as biomarkers of intestinal injury fol-
lowing irradiation. Using sophisticated statistical analysis, sub-
sequent pathway analysis suggested dysregulation in arachidonic 
acid metabolism, eicosanoid signaling, and oxidative phospho-
rylation. One of the significant challenges of defining biomarkers 
specific to radiation exposure is rationalization of metabolomics 
findings in a biological context. This study exhibited the poten-
tial of using metabolomics for the identification of biomarkers 
indicative of tissue-specific injury.
Importantly, rodent models have also been used to explore 
the possibility that radiations of differing quality [high linear 
energy transfer (LET) compared to low LET] result in different 
metabolomics profiles. Metabolomic profiles of intestinal speci-
mens from mice exposed to 137 cGy gamma irradiation versus an 
equitoxic 56Fe heavy ion irradiation exposure were evaluated with 
UPLC-QTOF-MS techniques (56). Biological relevance of both 
radiation exposures was evaluated using pathway analysis, immu-
noblots, and immunohistochemistry. Although exposures to both 
types of radiation resulted in perturbed amino acid metabolism 
profiles, PCA and OPLS-DA analysis suggested that metabolomic 
profiles differed. Specifically, 56Fe radiation preferentially affected 
dipeptide metabolism and resulted in elevation of prostanoid 
biosynthesis and eicosanoid signaling that is involved in cellular 
inflammation implicated in bowel disease.
It is anticipated that radiation metabolomics may eventually be 
used to study radiation damage as well as to identify biomarkers 
related to successful radiotherapy response. In a mouse xenograft 
model of human pancreatic cancer, high-resolution magic angle 
spinning proton magnetic resonance spectroscopy was used to 
monitor metabolomic changes in tumor specimens before and 
after radiotherapy. Tumor growth was inhibited proportionally 
to three increasing doses of radiation. The exposure to escalating 
radiation dose resulted in an increase in choline, taurine, alanine, 
isoleucine, leucine, valine, lactate, and glutamic acid in the tumor 
tissue whereas a depletion of endogenous phosphocholine, 
glycerophosphocholine, and betaine were observed (57). These 
results indicate that there is potential for the use of radiation 
metabolomics in the therapeutic fields for early detection and 
treatment of cancer.
CLiNiCAL STUDieS USiNG THe 
MeTABOLOMiCS APPROACH
Blood or urinary metabolomics is a promising biomarker dis-
covery platform owing to their minimally invasive properties. 
Radiation metabolomics using clinical samples are constrained by 
ethical considerations, such that majority of investigations have 
focused on the use of a controlled, generalized radiation exposure 
that can only be performed in the laboratory setting on animals 
rather than on human subjects. Primates are considered the 
closest animal model to humans. Thus, radiation metabolomics 
studies on non-human primates are a valuable surrogate. Using 
UPLC-ESI-QTOFS MS, Johnson and colleagues used untargeted 
and targeted metabolomics techniques to analyze urine from 
rhesus monkeys exposed to various gamma radiation (1, 3.5, 6.5, 
8.5 Gy) at various time points within 3 days post-irradiation (58). 
As many as nine novel and robust markers of IR in non-human 
primates (such as adipic acid) were identified. Some biomarkers 
identified in the rhesus model were shared by mouse and rat irra-
diation biomarker models (such as N-acetyltaurine and isethionic 
acid). Identified biomarkers of irradiation in the non-human pri-
mate model were metabolites belonging to DNA damage, taurine 
metabolism, and creatine and creatinine pathways. Inter-species 
comparison of biomarkers of radiation exposure picked out tau-
rine as a common metabolite between the mouse, rat, non-human 
primate, and humans and demonstrated similar metabolite profile 
between the same species, such as the humans and non-human 
primate (metabolites such as carnitine, acetyl carnitine, hypox-
anthine, creatine) and the mouse and the rat model (metabolites 
such as thymidine, N-hexanoylglycine, 2′-deoxyxanthosine, 
2′-Deoxyuridine) (Table 1) (49, 50, 58–62). Even though other 
studies have reported several radiation biomarkers, the limita-
tion of converting biomarker panels from discovery to clinical 
application requires a more concerted effort. One of the biggest 
challenges is the lack of preclinical biomarkers that can detect risk 
of IR exposure before the appearance of clinical symptoms (63). 
One way to overcome this is to combine several biomarkers from 
different “omics” assays to improve the sensitivity of the assays or 
techniques we use for the detection. Additionally, we can improve 
the study design by stratifying sub groups (63).
The first radiation metabolomics study of human urine 
post-exposure to full body radiation of patients undergoing 
radiotherapy was published recently (59). Ultra-performance 
LC combined with time-of-flight mass spectrometry (TOFMS) 
was used to analyze urine of patients who had received total 
body irradiation before undergoing hematopoietic stem-cell 
TABLe 1 | inter-species comparison of metabolites of radiation exposure 
that can vary with respect to dose, type, and time.
Metabolite Observed 
change
Species Reference
3-Hydroxy-2-
methylbenzoicacid
↑
Rodents
(48)
3-O-sulfate ↑ (48)
SAA levels ↑ (59)
Xanthosine ↑ (49)
N-Hexanoylglycine ↑ (60)
2′-Deoxyxanthosine ↑ (57)
2′-Deoxyuridine ↑ (57)
Thymidine ↑ (57)
N1-Acetylspermidine ↑ (60)
Glyoxylate ↑ (61)
Threonate ↑ (61)
p-Cresol ↑ (61)
N-Acetylglucosamine/
galactosamine-6-sulfate
↑ (60)
Tyrosol sulfate ↑
Non-human primate
(57)
3-Hydroxytyrosol sulfate ↑ (57)
N-Acetylserotonin sulfate ↑ (57)
Tyramine sulfate ↑ (57)
Adipic acid ↑ (57)
Creatinine ↑ (57)
Creatine ↑ (57)
Tri methyl-I-lysine ↓
Human
(58)
Decanoylcarnitine ↑ (58)
Octanoylcarnitine ↓ (58)
Xanthine ↑ Rodents/non-human 
primate/human
(57)
Taurine ↑ (57)
Acetylcarnitine ↓ Non-human primate/
rodents
(58)
Hypoxanthine ↑ (57)
Uric acid ↑ (57)
N-Acetyltaurine ↑ Non-human primate/
rodents
(57)
Isethionic acid ↑ (57)
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transplantation. Of the seven markers that showed differential 
expression pre- and post- irradiation, several were identified as 
players in the transport of fatty acids across mitochondria for 
consequent fatty acid β-oxidation. Other metabolites identified 
as differentially expressed in irradiated samples have been associ-
ated with increased oxidative stress and radiation-induced DNA 
damage. Interestingly, gender differences were also present in the 
post-irradiated samples.
However, biomarkers of radiation exposure that have been 
derived from human subjects so far may be confounded by 
cancer-specific markers, which may not be generalizable to 
“healthy” subjects exposed to larger or longer duration doses of 
radiation. Nevertheless, radiation oncology may gain much from 
radiation metabolomics studies. Metabolomic studies of cancer 
patients may help determine appropriate doses for radiotherapy 
and for disease prognosis (64). Wibom and colleagues sampled 
the intracranial fluid of patients with glioblastoma multiforme 
(GBM) after radiation therapy in areas of tumor and healthy 
tissue surrounding the tumor using a micro-dialysis catheter 
(65). GC-MS metabolomics profiling revealed many differences 
between healthy and tumor tissue profiles. The extensive panel 
of markers had ROC values of 0.896 and 0.821 for tumor and 
healthy brain tissue, respectively. The invasive nature of the 
micro-dialysis catheter makes the technique described in this 
study impractical for clinical use and needs to be validated in 
a more amendable matrix like serum, urine, or plasma. Tandle 
and colleagues characterized urinary metabolomes associated 
with GBM patients and applied radiotherapy. They were able to 
devise a predictive cluster of metabolites with accuracy of 73% 
in identifying pre-radiation versus post-radiation cohorts. They 
observed elevation of N-acetylated metabolites and TCA cycle 
intermediates in the post-radiation cohort (66). The findings 
of this study are consistent with other studies that have identi-
fied similar metabolites post-irradiation. For example, elevated 
N-acetylated compounds were observed in the study of Johnson 
and colleagues of irradiated rat’s urine (61) whereas Wibom’s 
work reported increase in TCA cycle intermediates (65).
FUTURe OF RADiATiON MeTABOLOMiCS 
wiTH OTHeR SYSTeMS BiOLOGY 
PLATFORMS
“Systems biology” has developed in popularity, although the 
term has been used broadly and its definition is dependent on 
context (67–70). Large scale studies have focused on radiation 
therapy acute and late effects. Such investigations contribute to 
the systems approach and help to establish the clinical efficacy 
of metabolomics in radiotherapy dosimetry (Figure 3). Systems 
biology-based studies may facilitate prospective design of adap-
tive clinical trials, where aspects of the trial can be modified based 
on analysis of data (71). Furthermore, bio-fluid samples may be 
collected and stored until patients with similar characteristics and 
therapy exposures are available for comparison.
Systems biology can be defined as one of the two types (72). 
Type I systems biology is a term used to describe collecting 
large amounts of data and analyzing the data together (73). In 
practice, principles of Type I systems biology is already being 
applied to radiation biology: although beyond the scope of this 
review, studies of the consequences of radiation on the genome or 
transcriptome (74, 75) and proteome (76, 77) are reported in the 
literature. Although technology seems to have advanced enough 
to generate broad Type I systems biology-level profiling of patients 
at many molecular and phenotypic levels, such in-depth profiling 
in the clinic has yet to be greatly applied in radiation research, or 
in any other field. A Type II systems biology approach models 
networks as complex systems by applying principles of systems 
theory (72). Both Type I and Type II systems biology approaches 
require extensive computational, statistical, mathematical, and 
bioinformatics techniques and further advancements in the field 
of bioinformatics and computational biology. In future, profiling 
and generation of data at multiple molecular and phenotypic levels 
may become clinically available in order to facilitate a “systems-
level” health status evaluation for the general population (78).
Use of advanced mathematical, statistical, and computational 
modeling for evaluation of large datasets generated from multi-
ple clinical and molecular parameters to understand radiation 
biology has already been advanced (79, 80) and, at least at an 
FiGURe 3 | Systems biology approach to radiation research.
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elementary level, implemented in practice (70). For example, the 
clinical cooperation group “CCG Personalized Radiotherapy in 
Head and Neck Cancer” includes the Research Unit of Radiation 
Cytogenetics at Helmhotz-Zentrum Munchen and the Radiation 
Oncology Clinics of the Ludwig-Maximilians Universitat 
Munchen, reports applying systems biology practices to collect 
genomic copy number profiles, HPV status typing, miRNA profil-
ing, and genetic analysis from cohorts to identify candidate radia-
tion sensitivity modulators for improved radiation therapy of head 
and neck squamous cell carcinoma. Integrated analysis of these 
heterogeneous datasets is then applied to models of cell culture 
to perform “perturbation experiments, network reconstruction, 
and modeling of radiation-response” (70). In this state-of-the-art 
translational approach for improving radiation therapy, metabo-
lomics is not one of the platforms used. As promising as metabo-
lomics has been for making basic science discoveries, the field 
is fertile for translating and integrating data from many systems 
biology platforms with metabolomics studies to advance radiation 
dosimetry, tailor radiotherapy, and generate basic knowledge for 
the improvement and protection of human health.
CONCLUSiON
Technology continues to drive the metabolomics field; given 
the plethora of reported studies that use LC-MS, it is reasonable 
to assume that this is the technological platform of choice for 
metabolomic data acquisition based on ease of use and accuracy. 
Moreover, multivariate analysis of large datasets is still evolving, 
using PCA and support vector machines to identify markers of 
interest. Metabolomics studies have, in part, validated classical 
pathways of radiation damage, including oxidative stress and 
subsequent DNA breakdown. Additionally, PUFA metabolism is 
often disrupted as an inflammatory effect of radiation exposure. 
Radiation metabolomics especially with clinical cohort studies is 
still in nascent stages. Clearly there is a great need for develop-
ment of biomarkers that would have immediate clinical relevance; 
these biomarkers could be used for patient triage in a radiological 
situation as well as for predicting response or non-response to 
radiation therapy.
In summary, technological advances in detection, acquisi-
tion, and processing have made the metabolomics platform 
a reliable source of data collection, there is still however, an 
urgent need for standardization of protocols and analytical 
methods to validate these biomarkers and enable their use 
in the clinical or translational science settings. Careful and 
systematic collection, processing and storage of bio fluids are 
critical for downstream metabolomic studies for validation of 
research findings across institutions and for future systems 
biology analyses.
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